Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Receivables: 2013-2024

Historic Receivables for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $136.5 million.

  • Amphastar Pharmaceuticals' Receivables rose 5.19% to $147.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $562.1 million, marking a year-over-year increase of 7.05%. This contributed to the annual value of $136.5 million for FY2024, which is 18.74% up from last year.
  • According to the latest figures from FY2024, Amphastar Pharmaceuticals' Receivables is $136.5 million, which was up 18.74% from $114.9 million recorded in FY2023.
  • Amphastar Pharmaceuticals' Receivables' 5-year high stood at $136.5 million during FY2024, with a 5-year trough of $66.0 million in FY2020.
  • Moreover, its 3-year median value for Receivables was $114.9 million (2023), whereas its average is $113.5 million.
  • Data for Amphastar Pharmaceuticals' Receivables shows a peak YoY spiked of 45.46% (in 2020) over the last 5 years.
  • Amphastar Pharmaceuticals' Receivables (Yearly) stood at $66.0 million in 2020, then grew by 19.39% to $78.8 million in 2021, then grew by 13.20% to $89.2 million in 2022, then increased by 28.85% to $114.9 million in 2023, then increased by 18.74% to $136.5 million in 2024.